Viriom successfully completes clinical safety trial with novel NNRTI, advances to efficacy studies in HIV-infected patients, and to development of HIV microbicide formulation
The Russian Corporation of Nanotechnologies (known as Rusnano) in Moscow, along with a yet-to-be announced co-investor, plans to fund the development of up to 15 potential drug molecules that have unique mechanisms of action, taking them from the preclinical development stage through to Phase 2 clinical trials. "We expect that of the 15 compounds, a few will support the investment," says Andrey Ivaschenko, chairman of ChemRar, the Moscow-based pharmaceutical and biotechnology services company that will provide the first five target molecules. Although the investment is not a huge sum, he notes, a compound can be developed to the Phase 2 clinical stage in Russia for $5-10 million.
Rabochaya St. 2-a, bldg. 1
Khimki, Moscow
141400, Russia
Phone: +7 (495) 995-4944
Fax: +7 (495) 626-9780
www.viriom.com
PRESS RELEASE
PRESS RELEASE
.png)
Viriom successfully completes clinical safety trial with novel NNRTI, advances to efficacy studies in HIV-infected patients, and to development of HIV microbicide formulation
Moscow, Russia – June 21, 2011 – Viriom, biotech company established in ChemRar High Tech Center, Khimki, Moscow Russia, announced today a successful completion of phase one clinical trials in development of novel NNRTI treatment for HIV.
Phase I clinical studies, conducted by Viriom in the Research Center for Preventive Medicines in Moscow, confirmed that the oral drug, VM-1500, was safe and well-tolerated, no serious adverse effects were observed. The results of the Phase I study allow the company to advance to the clinical efficacy studies on HIV-infected patients. Viriom is also developing a topical gel formulation for VM-1500, to lower the incidence of sexually-transmitted HIV.
“We are very pleased with the results of the clinical studies to date”, said Dr. Vadim Bichko, ChemDiv’s VP and Head, Infectious Diseases, who leads the HIV program for Viriom in San Diego and Moscow. “Besides good safety and tolerability, VM-1500 had shown unique pharmacokinetic properties in humans, and has a potential of becoming the best drug in its class. If the topical gel formulation proves effective, VM-1500 will help to curb AIDS epidemic in developing countries in Africa and around the globe.”
Viriom is supported by the Presidential Commission for Modernization of the Russian Federation to aid second round of its financing for completing development, registration and manufacturing of novel antivirals in Russia and other countries.
“The continuing support of the Commission allows us to build on success of our early development program, expanding to additional indications with broad clinical impact for HIV treatment and prevention”, said Dr. Irina Tyrnova, Viriom’s Chief Executive Officer. “We are very appreciative of the Russian government’s attention to developing innovative medicines for HIV.”
Media Contact:
Irina Tyrnova
CEO, Viriom LLC
_CLOAKING
About Viriom:
Viriom Ltd is an innovative company established in 2009 at ChemRar High Tech Center in Moscow, Russia discovering, partnering and developing novel targeted medicines for HIV/AIDS treatment. Viriom has licensed from Roche novel NNRTI drugs for development and commercialization. www.viriom.com
About ChemRar:
Non for profit organization (NFPO) ChemRar High-Tech Center is a unique pharma and biotechnology conglomerate built in Moscow, Russian Federation by highly innovative life science R&D organizations, discovering, developing and commercializing novel drugs for partners in Russia and worldwide. We bring novel therapies for unmet medical needs in treating CNS, oncology, cardiovascular, metabolic and infectious disease.www.chemrar.ru
« Back